Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine–erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial)

被引：0

作者：

Joan Maurel

Santiago Sánchez-Cabús

Berta Laquente

Lydia Gaba

Laura Visa

Joan Fabregat

Ignacio Povés

Susana Roselló

Roberto Díaz-Beveridge

Marta Martín-Richard

Javier Rodriguez

Luis Sabater

Carles Conill

María Cambray

Ana Reig

Juan Ramón Ayuso

Carlos Valls

Antonio Ferrández

Josep Antoni Bombí

Angels Ginés

Xabier García-Albéniz

Laureano Fernández-Cruz

机构：

[1] IDIBAPS,Surgical Department, Hospital Clínic Barcelona

[2] University of Barcelona,Medical Oncology Department

[3] Institut Català d’Oncologia,Medical Oncology Department, Hospital Clínic, Translational Genomics and Targeted Therapeutics in Solid Tumors Group

[4] IDIBAPS,Department of Oncology

[5] University of Barcelona,Surgical Department

[6] Hospital Mar,Surgical Department

[7] Hospital Bellvitge,Medical Oncology Department

[8] Hospital del Mar,Medical Oncology Department

[9] Hospital Clínico Valencia,Medical Oncology Department

[10] Hospital La Fe,Medical Oncology Department

[11] Hospital Sant Pau,Surgical Department

[12] Hospital Clínico Universitario Navarra,Radiotherapy Oncology Department, Hospital Clínic Barcelona

[13] Hospital Clínico Valencia,Radiotherapy Oncology Department

[14] IDIBAPS,Radiotherapy Oncology Department

[15] University of Barcelona,Radiology Department, Hospital Clínic Barcelona

[16] Institut Català d’Oncologia,Radiology Department

[17] Hospital Mar,Pathology Department

[18] IDIBAPS,Pathology Department, Hospital Clínic Barcelona

[19] University of Barcelona,Gastrointestinal Department, Hospital Clínic Barcelona

[20] Hospital Bellvitge,undefined

[21] Hospital Clínico Valencia,undefined

[22] IDIBAPS,undefined

[23] University of Barcelona,undefined

[24] IDIBAPS,undefined

[25] University of Barcelona,undefined

[26] Harvard T.H. Chan School of Public Health,undefined

来源：

Cancer Chemotherapy and Pharmacology | 2018年 / 82卷

关键词：

Neoadjuant; Pancreatic; Adenocarcinoma;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：935 / 943

页数：8

共 50 条

[21] A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)
Halfdanarson, Thorvardur R.
Foster, Nathan R.
Kim, George P.
Meyers, Jeffrey P.
Smyrk, Thomas C.
McCullough, Ann E.
Ames, Matthew M.
Jaffe, Jeffrry P.
Alberts, Steven R.
ONCOLOGIST, 2019, 24 (05): : 589 - +
[22] Erlotinib plus Gemcitabine in metastatic pancreatic cancer: Results from a non-interventional trial
Westphalen, C. Benedikt
Heinemann, Volker
Tessen, Hans Werner
Groschek, Matthias
Hoeffkes, Heinz-Gert
Marschner, Norbert
Schulze, Mathias
Beringer, Andreas
Waldschmidt, Dirk
ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2020, 58 (04): : 332 - 340
[23] A randomized phase II clinical trial of gemcitabine, oxaliplatin, erlotinib combination chemotherapy versus gemcitabine and erlotinib in previously untreated patients with locally advanced or metastatic pancreatic cancer.
Lim, Sung Hee
Yun, Jina
Lee, Min-Young
Kim, Han Jo
Kim, Kyoung Ha
Kim, Se Hyung
Lee, Sang-Cheol
Bae, Sang Byung
Kim, Chan Kyu
Lee, Namsu
Lee, Kyu Taek
Park, Sung Kyu
Hong, Dae Sik
Choi, Hyun Jong
Moon, Jong Ho
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[24] Gemcitabine plus erlotinib (GE) followed by capecitabine (C) versus capecitabine plus erlotinib (CE) followed by gemcitabine (G) in advanced pancreatic cancer (APC): A randomized, cross-over phase III trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
Boeck, S. H.
Vehling-Kaiser, U.
Waldschmidt, D.
Kettner, E.
Maerten, A.
Winkelmann, C.
Klein, S.
Kojouharoff, G.
Jung, A.
Heinemann, V.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
[25] A Randomized Phase 2 Trial of Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer: Gemcitabine Alone Versus Gemcitabine Combined with Cisplatin
Daniel H. Palmer
Deborah D. Stocken
Helen Hewitt
Catherine E. Markham
A. Bassim Hassan
Philip J. Johnson
John A. C. Buckels
Simon R. Bramhall
Annals of Surgical Oncology, 2007, 14 : 2088 - 2096
[26] A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: Gemcitabine alone versus gemcitabine combined with cisplatin
Palmer, Daniel H.
Stocken, Deborah D.
Hewitt, Helen
Markham, Catherine E.
Hassan, A. Bassim
Johnson, Philip J.
Buckels, John A. C.
Bramhall, Simon R.
ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (07) : 2088 - 2096
[27] A phase I trial of erlotinib, gemcitabine and radiation for patients with locally advanced, unresectable pancreatic cancer.
Kortmansky, JS
O'Reilly, EM
Minsky, BD
Puleio, SA
Winkelmann, J
Kelsen, DP
Schwartz, GK
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 334S - 334S
[28] Phase I Trial of Gemcitabine Combined with Capecitabine and Erlotinib in Advanced Pancreatic Cancer: A Clinical and Pharmacological Study
Francois, E.
Bennouna, J.
Chamorey, E.
Etienne-Grimaldi, M. C.
Renee, N.
Senellart, H.
Michel, C.
Follana, P.
Mari, V.
Douillard, J. Y.
Milano, G.
CHEMOTHERAPY, 2012, 58 (05) : 371 - 380
[29] Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial
Tomislav Dragovich
Mark Huberman
Daniel D. Von Hoff
Eric K. Rowinsky
Paul Nadler
Debra Wood
Marta Hamilton
George Hage
Julie Wolf
Amita Patnaik
Cancer Chemotherapy and Pharmacology, 2007, 60 : 295 - 303
[30] Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial
Lim, Sung Hee
Yun, Jina
Lee, Min-Young
Kim, Han Jo
Kim, Kyoung Ha
Kim, Se Hyung
Lee, Sang-Chul
Bae, Sang Byung
Kim, Chan Kyu
Lee, Namsu
Lee, Kyu Taek
Park, Seong Kyu
Lee, Yun Nah
Moon, Jong Ho
YONSEI MEDICAL JOURNAL, 2021, 62 (08) : 671 - 678

← 1 2 3 4 5 →